Tuoxin Pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 0/6
Tuoxin Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 8.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.9% per year.
Key information
8.2%
Earnings growth rate
3.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.9% |
| Return on equity | -4.6% |
| Net Margin | -17.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tuoxin Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 415 | -73 | 74 | 45 |
| 30 Jun 24 | 397 | -68 | 80 | 45 |
| 31 Mar 24 | 393 | -59 | 81 | 54 |
| 31 Dec 23 | 836 | 243 | 106 | 51 |
| 30 Sep 23 | 1,108 | 490 | 150 | 47 |
| 30 Jun 23 | 1,195 | 542 | 137 | 40 |
| 31 Mar 23 | 1,206 | 562 | 131 | 31 |
| 01 Jan 23 | 785 | 287 | 104 | 31 |
| 30 Sep 22 | 537 | 109 | 86 | 26 |
| 30 Jun 22 | 465 | 66 | 85 | 24 |
| 31 Mar 22 | 488 | 64 | 80 | 22 |
| 01 Jan 22 | 502 | 66 | 77 | 21 |
| 30 Sep 21 | 531 | 96 | 65 | 20 |
| 30 Jun 21 | 568 | 114 | 60 | 22 |
| 31 Mar 21 | 550 | 117 | 60 | 20 |
| 31 Dec 20 | 528 | 113 | 57 | 19 |
| 01 Jan 20 | 386 | 61 | 55 | 16 |
| 01 Jan 19 | 391 | 63 | 61 | 13 |
| 30 Sep 17 | 373 | 24 | 51 | 0 |
| 30 Jun 17 | 345 | 13 | 51 | 0 |
| 31 Mar 17 | 330 | 10 | 52 | 0 |
| 31 Dec 16 | 315 | 6 | 54 | 0 |
| 30 Sep 16 | 325 | 9 | 55 | 0 |
| 30 Jun 16 | 334 | 13 | 55 | 0 |
| 31 Mar 16 | 349 | 16 | 56 | 0 |
| 31 Dec 15 | 364 | 19 | 57 | 0 |
| 30 Sep 15 | 365 | 18 | 55 | 0 |
| 30 Jun 15 | 366 | 18 | 52 | 0 |
| 31 Mar 15 | 371 | 16 | 49 | 0 |
| 01 Jan 15 | 376 | 15 | 46 | 0 |
| 01 Jan 14 | 374 | 18 | 46 | 0 |
Quality Earnings: 301089 is currently unprofitable.
Growing Profit Margin: 301089 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301089 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare 301089's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 301089 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Return on Equity
High ROE: 301089 has a negative Return on Equity (-4.64%), as it is currently unprofitable.